loading page

Malignant Pericardial Effusion and Cardiac Buffering are Initial Manifestations of Endometrial Cancer
  • +2
  • Raúl Villanueva Rodríguez,
  • Ramón de los Santos Aguilar,
  • Luis David Sol Oliva,
  • Alberto Vielma Valdez,
  • Hugo Carlos González García
Raúl Villanueva Rodríguez
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Corresponding Author:raul.villanuevar@incmnsz.mx

Author Profile
Ramón de los Santos Aguilar
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author Profile
Luis David Sol Oliva
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author Profile
Alberto Vielma Valdez
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Author Profile
Hugo Carlos González García
Hospital General Dr Manuel Gea Gonzalez
Author Profile

Abstract

Background: Malignant pericardial effusion with cardiac buffer secondary to endometrial cancer is exceptional and can be fatal for these patients if it is not recognized in time; however, due to the rarity of this type of case, there is no standardized treatment. Case: We present the case of a patient who went to emergency room due to dyspnea of small exertion that worsened; upon arrival, data of pulmonary thromboembolism were corroborated, and in secondary studies, data of cardiac tamponade were observed, and pericardial window was performed as initial treatment draining 750 mL of pericardial fluid. Later, a cytopathological study of the pericardial fluid revealed adenocarcinoma cells, continuing its diagnostic approach, and found that the primary tumor was adenocarcinoma of the endometrium. Conclusion: Cardiac tamponade is a rare and fatal complication, which makes it a complex pathology for diagnosis and treatment. Therefore, it is important to publicize this type of case to improve current management.
25 Jan 2024Reviewer(s) Assigned
15 Apr 2024Review(s) Completed, Editorial Evaluation Pending
18 Jun 20241st Revision Received
31 Jul 2024Submission Checks Completed
31 Jul 2024Assigned to Editor
31 Jul 2024Review(s) Completed, Editorial Evaluation Pending
01 Aug 2024Reviewer(s) Assigned